Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)	1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	May 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($) target
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Selling, general and administrative expenses					$ 262,600,000	$ 215,300,000	$ 503,700,000	$ 430,500,000
Acquired in-process research and development expenses					110,500,000	61,900,000	457,600,000	63,900,000
Catalyst Biosciences
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Asset acquisition, consideration transferred			$ 60,000,000
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, right to exclusively license, number of targets | target										3
Collaborative arrangement, development and regulatory potential milestone payments maximum										$ 410,000,000
CRISPR JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum									$ 200,000,000
Allocation of net profits and net losses, percent									60.00%
Research and development expenses					57,800,000	38,900,000	118,300,000	75,100,000
Selling, general and administrative expenses					23,600,000	$ 12,100,000	40,100,000	$ 21,900,000
CRISPR JDCA | CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of net profits and net losses, percent									40.00%
CRISPR T1D
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum							160,000,000
Up-front payment	$ 100,000,000
Acquired in-process research and development expenses					$ 70,000,000		$ 170,000,000
CRISPR T1D | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment				$ 70,000,000
Entrada Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum		$ 485,000,000
Up-front payment		225,100,000
Purchase of common stock		$ 24,900,000